Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
ATRIAL FIBRILLATION ABLATION IN PATIENTS WITH SEVERELY DEPRESSED EJECTION FRACTION. META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.
Anno:
2023
Introduction Atrial fibrillation (AF) and severely depressed ejection fraction (SDEF) are two conditions that often coexist. AF increases overall mortality in these patients. The current available guidelines do not provide a clear consensus regarding the best management approach. We conducted this meta-analysis in order to determine if catheter ablation…
Leggi di più
POSTERIOR WALL CHARACTERIZATION IN PATIENTS AFFECTED BY ATRIAL FIBRILLATION
Anno:
2023
Background. Several clinical data in humans demonstrate that atrial fibrillation (AF) dominant frequencies and rotors are mostly localized on the posterior wall (PW), but the correlation among these phenomena and abnormal conduction properties during sinus (SR) and paced rhythm (PR) has never been analyzed. Aims. To provide a characterization…
Leggi di più
Cryoballoon Ablation for Atrial Fibrillation in Octogenarians: a propensity-score matching comparison with a cohort of younger patients
Anno:
2023
Background: Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia in adults with a current estimated prevalence between 2-4% in the general population. AF prevalence increases with advancing age and it is estimated that nearly 10% of octogenarians may be affected by this arrhythmia. In terms of safety…
Leggi di più
Functional mapping: a new approach for substrate characterization in patients affected by atrial fibrillation
Anno:
2023
Background. The ongoing challenge is to generate meaningful data during electrophysiological (EP) studies, integrating the knowledge on atrial fibrillation (AF) progression gained by the EP community in the latest years. At the present time there is a lack of EP protocols and none of the most used approaches take in consideration…
Leggi di più
ORAL ANTICOAGULATION THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION AND CANCER: A LITERATURE REVIEW
Anno:
2023
INTRODUCTION Cancer and atrial fibrillation (AF) are two very frequent conditions that share common pathophysiological and epidemiological features. Spontaneous coagulation is associated with malignant neoplasia as well as prothrombotic potential due to the overexpression of procoagulants. Balancing the increased and competing risks of clotting and bleeding in these patients…
Leggi di più
Double rhythm mapping for coherent electrophysiological substrate characterization in atrial fibrillation patients
Anno:
2023
Background. Atrial fibrillation (AF) progresses with a cascade of combined structural, functional, and systemic dysfunctions. Electro-anatomical maps are employed to investigate pro-arrhythmic areas. However, single rhythm maps provide only a partial reconstruction: rhythm and wavefront directionality might mask some of these areas. Purpose. To demonstrate that the combined quantitative analysis of…
Leggi di più
CHALLENGING MANAGEMENT OF ORAL ANTICOAGULANT THERAPY IN A OBESE PATIENT WITH DILATED CARDIOMYOPATHY, ATRIAL FIBRILLATION AND ICD LEAD THROMBUS
Anno:
2023
Obesity is a worldwide epidemic condition at high risk for AF development; nevertheless, obese patients are underrepresented in RCTs of anticoagulant agents. Robust evidence assessing efficacy of DOACs in these patients is lacking and, to date, major Associations do not recommend DOACs in patients > 120 Kg (BMI>40 Kg/m2)….
Leggi di più
Efficacy and safety of left atrial appendage closure compared with oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlled trials and propensity-matched studies
Anno:
2023
Backgrounds. In the recent years, two randomized controlled trials (RCTs), the PROTECT-AF trial and the PREVAIL trial demonstrated that in atrial fibrillation (AF) patients, left atrial appendage closure (LAAC) compared with oral anticoagulants (OAC), showed a non-inferiority in the prevention of stroke and even a reduction in mortality. Nevertheless,…
Leggi di più
EFFICACY AND SAFETY OF LEVOSIMENDAN IN AN ISCHEMIC CARDIOGENIC SHOCK POPULATION: A 10-YEARS SINGLE CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background: Levosimendan is a Ca²⁺-sensitizer with inodilator action able to improve cardiac contractility without increse oxygen demand. In AHF setting clinical trial and registries showed an improvement in systemic haemodynamics without a decrease in in-hospital mortality. Purpose: evaluate safety and efficacy of Levosimendan in an ischemic CS population. Methods:…
Leggi di più
VIP-AF. Correlation between Voltage and Impedance mapping in Patients affected by Atrial Fibrillation: a further step towards substrate characterization
Anno:
2023
Background. Pulmonary veins isolation (PVI) represents the main strategy for paroxysmal atrial fibrillation (AF) treatment. Due to the poor clinical outcomes of PVI in case of non-paroxysmal AF, significant efforts have been made to develop new ablative strategies to modify the atrial substrate. Up to now, in order to…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram